Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(50.0%)
Phase 1
3(50.0%)
6Total
Early Phase 1(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07394205Early Phase 1Not Yet Recruiting

Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer

Role: collaborator

NCT06705725Phase 1Not Yet Recruiting

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Role: lead

NCT06461624Phase 1Recruiting

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

Role: collaborator

NCT04706936Phase 1Unknown

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Role: collaborator

NCT04803929Early Phase 1Recruiting

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

Role: lead

NCT04637269Early Phase 1Unknown

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Role: collaborator

All 6 trials loaded